PIBRENTASVIR – A REVIEW

Sravya Chowdary, Uttam Prasad Panigrahy, Konde Abbulu

Abstract


Pibrentasvir will come under Anti-viral drugs. It will be available as Brand name – Mavyret (Combination of Pibrentasvir & Glecaprevir).It is indicated for the treatment of adult patients with chronic Hepatitis C virus (HCV). Mavyret is contraindicated to the Patients with severe hepatic impairment (Child-Pugh C) and to the drugs like Rifampin or Atazanavir. The common adverse effects are Headache and fatigue. It is an NS5A inhibitor. It mainly works by blocking the interaction with the viral capsid protein, it inhibits the assembly of proteins & formation of HCV particles. In the present work, the developed method Chromatogram was run through  Kinetics Phenyl Hexyl C8 (150×4.6) mm, 2.6µm. Mobile phase contains a mixture of Buffer: ACN (70:30) was pumped through a flow rate of 1.0mL/min. Buffer used in this method was 0.01M of Potassium Di hydrogen phosphate in 1L of Milli Q water, pH to 2.8 with diluted OPA. Temperature of column and sample was maintained at 300C & 250C respectively. Optimized wavelength selected was 252nm.Retention time of pibrentasvir was found to be 38.454 min. % RSD of the pibrentasvir was found to be 0.9999. % Recovery was found to be 99.73 to 101.15 %.


Full Text:

PDF

References


Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T, Lu L, Dekhtyar T, Irvin M, Tripathi R, Maring C, Randolph JT, Wagner R, Collins C: In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother. 2017 Apr 24; 61(5): 02558-16.

Masaki T, Suzuki R, Murakami K, Aizaki H, Ishii K, Murayama A, Date T, Matsuura Y, Miyamura T, Wakita T, Suzuki T: Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol. 2008 Aug; 82(16):7964-76.

National Center for Biotechnology Information. Pub Chem Database. Pibrentasvir, CID=58031952, https://pubchem.ncbi.nlm.nih.gov/compound/58031952 (May 20, 2019) Page No: 7.1 Pharmacology.

Pibrentasvir-Drug bank, August 31, 2017 09:29 / Updated on May 01, 2019 11:53 (https://www.drugbank.ca/drugs/DB13878) Mechanism of action and Absorption.

Pibrentasvir-Drug bank, August 31, 2017 09:29 / Updated on May 01, 2019 11:53 (https://www.drugbank.ca/drugs/DB13878) present in the pharmacology.

National Center for Biotechnology Information. Pub Chem Database. Pibrentasvir, CID=58031952, https://pubchem.ncbi.nlm.nih.gov/compound/58031952 (accessed on May 20, 2019) Page No: 7.1 Pharmacology.

Pibrentasvir-Drug bank, August 31, 2017 09:29 / Updated on May 01, 2019 11:53 (https://www.drugbank.ca/drugs/DB13878) Mechanism of action and Absorption.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.